Sigma-Aldrich, Steinheim, Germany)
No claims are made regarding therapeutic application, clinical relevance, physiological outcomes, or suitability for human or veterinary use
The company backed its application with results from the Phase II/III QUILT-3.032 study, in which maintenance treatment with Anktiva plus BCG elicited a complete response rate of 62%, with duration of response exceeding 47 months at the November 2023 cut-off
The peptide was administered intravenously in varying intervals over seven days
The 1998 characterisation study for ipamorelin confirmed this selectivity in animal models: even at doses more than 200-fold above the effective GH-releasing dose, ACTH and cortisol were not significantly elevated [1]
Dysregulation of FoxO proteins, including FoxO4, is linked to metabolic diseases such as insulin resistance and type 2 diabetes